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Abstract
Background: The introduction of a GMP-certified 68Ga-generator spurred the
application of 68Ga-radiopharmaceuticals. Several radiosynthesis of 68Ga-
radiopharmaceuticals are more efficient and robust when performed with 2-[4-(2-
hydroxyethyl)piperazin-1-yl] ethanesulfonic acid (HEPES) buffer, which is considered
as an impurity in the quality control (QC) procedure. Thus, prior to clinical use, QC
must be conducted to ensure that HEPES does not exceed the maximum dose of
200 μg/V Injected as described in European Pharmacopoeia (Ph Eur) for edotreotide.
However, when applying the thin-layer chromatography (TLC) method described in
the Ph Eur to quantify the HEPES amount present in the 68Ga-octreotide or in the
remaining 68Ga-radiopharmaceuticals that were tested, no amount was detectable
after 4 min of iodine incubation. Here we tested our modified TLC method and
validate a new high-performance liquid chromatography (HPLC) method to quantify
HEPES in 68Ga-radiopharmaceuticals and compare it to the TLC-method described in
Ph Eur. In addition, samples collected from various institutes were tested to evaluate
whether the synthesis of different 68Ga-radiopharmaceuticals or the use of different
synthesis methods could affect the amounts of HEPES.
Results: HEPES could not be detected by the TLC method described in the Ph Eur
within 4 min incubation in an iodine-saturated chamber. As for our modified TLC
method, only after 2 h, spots were only visible > 1 mg/mL. The HPLC method had a
limit-of-quantification (LOQ) of 3 μg/mL and a limit-of-detection (LOD) of 1 μg/mL.
From the three 68Ga-radiopharmaceuticals tested, only in the [68Ga]Ga-NODAGA-
Exendin samples exceeding amounts of HEPES were found and its concentration in
the [68Ga]Ga-NODAGA-Exendin was significantly higher, when compared to [68Ga]Ga-
DOTATOC and [68Ga]Ga-PSMA-11.
Conclusion: The TLC method described in Ph Eur and our modified TLC method
may not be sufficiently sensitive and thus unsuitable to use for QC release. The new
HPLC method was sensitive, quantitative, reproducible and suitable for QC release.
With this method, we were able to determine that some 68Ga-radiopharmaceuticals
may exceed the HEPES limit of 200 μg/ V Injected. This new analytical system would
allow correcting for the maximum injected dose in order not to exceed this amount.
Keywords: 68Ga-radiopharmaceuticals, HEPES, HPLC and quality control
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Background
In the last two decades, the development and use of 68Ga-based radiopharmaceuticals
had continuously grown worldwide. Some of the important reasons for such progress
are the availability of GMP-certified 68Ge/68Ga generators, diverse and robust radiola-
belling chemistry and the potential for personalized medicine and for theranostic use
(Velikyan 2013).
68Ga can be labeled to a wide range of ligands specifically targeting receptors, en-
zymes, and antigens; small effectors or hapten molecules for pre-targeting imaging and
molecules with a biological function to image biological properties and /or processes
such as hypoxia, glycolysis, apoptosis, angiogenesis, and proliferation (Velikyan 2015).
68Ga-radiopharmaceuticals have been mostly applied in oncology in imaging
prostate-specific membrane antigen (PSMA), somatostatin receptors (SSTR), glucagon-
like peptide 1 receptors (GLP1R) and many more. However, it has also shown potential
for imaging pulmonary or myocardial perfusion as well as infection and inflammation
(Velikyan 2015).
During the radiolabelling of 68Ga-radiopharmaceuticals, a buffer must be used to as-
sure the correct pH for the incorporation of 68Ga radionuclide. The most common
buffers used in these labeling are sodium acetate, ammonium acetate and 2-[4-N-(2-
hydroxyethyl)-1-piperazinyl]-N′-ethanesulfonic acid (HEPES). Some 68Ga radiolabelling
reactions have shown to be more efficient and stable when performed with a HEPES
buffer solution (Sasson et al. 2010).
HEPES is a zwitterionic compound that is widely used in cell culture due to its higher
capacity to maintain physiological pH despite the increasing contents of CO2 produced
by cellular respiration. HEPES is considered to be an impurity and at present, informa-
tion regarding HEPES toxicity is lacking. Therefore, despite being considered eligible
for human use, doubts still remain regarding its safety in humans (Meyer et al. 2004).
The European Pharmacopeia (Ph Eur) has considered the HEPES present in 68Ga-ra-
diopharmaceuticals as an impurity which should not exceed the maximum dose of
200 μg/ V Injected (01/2013:2482 Gallium (68Ga) Edotreotide injection 2011). The Ph
Eur has included a TLC method for the detection of HEPES which should be per-
formed prior to release. However, when applying this TLC method to detect the HEPES
present in the 68Ga-radiopharmaceuticals within the 4 min incubation with Iodine, no
spot was visible.
This led us to test a modified TLC method to see if detection of the HEPES would
improve and in addition, to develop a new HPLC method to quantify the HEPES
amount present in solutions (Antunes et al. 2017). Here we compare the TLC methods
with a faster and reliable quantitative HPLC method to determine the amounts of
HEPES present in the final formulated 68Ga-radiopharmaceuticals.
Methods
Reagents and solvents
68Ga synthesis kits and reagents were obtained from Advanced Biochemical Com-
pounds (ABX, Radeberg, Germany), ammonium formate, iodine beads, and HEPES
were obtained from Sigma-Aldrich. Silica gel 60 F245 (20 × 20 cm) TLC plates were
purchased from Merck.
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68Ga-radiopharmaceuticals
For 68Ga, a > 9month old GMP 1110MBq grade 68Ga-generator was used (Eckert & Zieg-
ler). Radiopharmaceuticals were synthesized in compliance with each institute’s GMP proto-
col. The syntheses were performed using a GRP® synthesis module from Scintomics
(Fürstenfeldbruck, Germany) with the cationic concentration protocol provided by Scin-
tomics. Briefly, the [68Ga]GaCl3 was concentrated on a PS-H
+ cartridge and eluted with a 5
M NaCl solution into a reaction vial containing either 5–10 μg PSMA-11 or 38 μg DOTA-
TOC, in 2mL of HEPES 1.5M buffer. The reaction mixture was allowed to react for 10
min at 100 °C. After cooling down, the mixture was trapped on a Sep-Pak C18 light (pre-ac-
tivated with EtOH and WFI) and subsequently eluted with 2mL of a mixture of EtOH/
water (1:1) and diluted in 16 and 18mL of PBS, respectively.
The radiolabelling of [68Ga]Ga-NODAGA-Exendin was performed according to the pro-
cedure described in literature (Franssen et al. 2015). Briefly,[68Ga]GaCl3 was eluted from the
PS-H+ cartridge (pre-activated with 5M NaCl in HCl 0.1M and WFI) with NaCl 5M in
0.1M HCl and allowed to react with 10 μg NODAGA-Exendin in 475 μL of HEPES 2.5M
and 50 μL of ascorbic acid (100mg/ml), for 10min at 95 °C. The mixture was cooled down,
2.0ml 50mM EDTA, 0.15% Tween-80 was added and passed through an HLB Plus light
cartridge (pre-activated with EtOH and WFI). After washing the cartridge with water, the
final product was eluted with 1mL of ethanol and diluted with 19mL of PBS.
All formulated products were sterilized by filtration over a 0.22 μm filter into a sterile
vial. The final products were released by quality control (QC) after routine tests.
TLC analysis
TLC analysis Ph Eur. method
The TLC analysis was performed according to the Ph Eur. The reference solution was
prepared as described (01/2013:2482 Gallium (68Ga) Edotreotide injection 2011).
Briefly, 10 mg of HEPES was dissolved in 10 mL water. From this solution, 1 mL was di-
luted to 50mL with water, resulting in a HEPES concentration of 0.02 mg/mL. From
this 0.02 mg/mL HEPES solution, 1 μL was spotted on a TLC silica gel F254 plate and
dried with a current of air. Once the spots was dried and not visible anymore, the TLC
plate was eluted with a solution of water/acetonitrile (25/75 v/v) as the mobile phase.
The elution was stopped when the front of the mobile phase reached 2/3 of the plate.
The plate was then dried and transferred to the iodine vapor chamber and incubated
for 4 min. After incubation, the plate was immediately scored for a positive signal (a
clear visible yellow spot corresponding to HEPES).
TLC analysis modified Ph Eur. method
The TLC analysis was performed according to the Ph Eur with minor modifications.
HEPES solutions with different concentrations ranging from 1 to 0.006 mg/mL were
prepared, using the matrix solution of the formulated samples (10% EtOH in PBS).
From each HEPES solution a total amount of 10 μL was spotted on 4 TLC silica gel
F254 plate (one for eact time of incubation). The volume of 10 μL was spotted in five
steps of 2 μL and dried with a gentle stream of air in-between. Once the spots were
dried and not visible anymore, the TLC plates were incubated in a TLC container and
eluted with a solution of water/acetonitrile (25/75 v/v) as the mobile phase. The
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incubation was stopped when the front of the mobile phase reached 2/3 of each plate.
The plates were dried and transferred to the iodine vapor chamber and incubated for 4
min according to the Ph Eur and 1, 2 or 24 h. After incubation, the plates were imme-
diately scored for a positive signal (a clear visible yellow spot) for any of the spotted
HEPES concentrations. This experiment was performed in triplicate.
HPLC analysis
HEPES solutions with concentrations ranging from 6 to 100 μg/mL were prepared with
the matrix solution of the formulated samples (10% EtOH in PBS). HPLC analysis was
performed with a Waters Acquiry QSm (quaternary solvent manager) pump system
using a Waters XBridge C18 column (150mm × 4.6 mm, 5 μm), connected to a Waters
Acquiry 4-class UV detector set to a wavelength of 195 nm. The mobile phase consisted
of ammonium formate 20 mM pH 9.5, at a flow rate of 1 mL/min). Chromatograms
were collected and analyzed with Empower 3 software® (Waters). Each sample was
tested in triplicate unless stated otherwise. The HPLC method was validated according
to the ICH Q2 (R1) guidelines (Borman and Elder 2017).
Calibration curve
Seven HEPES solutions with concentration ranging from 6 to 100 μg/mL were used for
each calibration curve. Each of these solutions was injected in triplicate and in 3 con-
secutive days. The final calibration curve was from the average of the 3 calibration
curves obtained in those 3 consecutive days.
Accuracy
The accuracy of the HPLC method was evaluated in triplicate at seven concentrations ran-
ging from 6 to 100 μg/mL. The accuracy value is expressed as the ratio between the value of
the determined HEPES concentration and the original standard know concentration.
Inter-day repeatability
Three solutions with different concentrations of HEPES (Low = 8 μg/mL; medium =
15 μg/mL and high = 50 μg/mL) were injected five times and in three consecutive days.
An F-test was applied to evaluate if there were any differences in the area of the peaks
obtained in each day.
Intra-day repeatability
For the intra-day analysis, we choose the solution with 15 μg/mL (medium concentra-
tion) which was the closest to the concentration we would perform our analysis (20 μg/
mL). This solution (15 μg/mL) was analyzed five times in the same day. The intra-day
repeatability is expressed as a relative standard deviation (RSD%).
Limit-of-detection (LOD) and limit-of-quantification (LOQ)
The LOD and LOQ for HEPES were determined at signal-to-noise ratios of 3:1 and 10:
1, respectively.
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Revalidation of the methods
Standard HEPES samples ranging from 6 to 100 μg/mL prepared in the two different
institutes were exchanged to the other institute to be tested either with the TLC (modi-
fied method) or the HPLC method depending of the institute (Fig. 1).
Solvent effect
HEPES samples (10 μg/mL) were prepared in either 10% (v/v) ethanol in PBS, PBS or
NaCl 0.9% to evaluate the matrix effect in the determination of HEPES in solution by
the HPLC method (Fig. 1). The experiment was performed in triplicate.
Determination of HEPES in different 68Ga-radiopharmaceuticals
Samples of [68Ga]Ga-DOTATOC; [68Ga]Ga-PSMA-11 and [68Ga]Ga-NODAGA-Exen-
din from different batches, for clinical use, were collected from different institutes and
tested in the institute where the HPLC method was developed. To assure that the
HEPES peak was not altered by the peak of the radiopharmaceutical, an injection of the
radiopharmaceutical without HEPES was performed (Fig. 2).
Statistics
Statistical analyses were performed with Excel 2010 (Microsoft) and GraphPad Prism
(version 7.02). Inter-day repeatability was analyses with an F-test. Differences in solvent
effects were analyzed using a two-sided unpaired Student’s t-test. Correlations were cal-
culated with the linear regression algorithm in GraphPad Prism (version 7.02) and were
considered statistically significant whenever r2 > 0.5 and p < 0.05. The revalidation of
the method was performed with a Pearson comparison. Differences of HEPES found in
Fig. 1 Scheme of the setup of the performed experiments
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different 68Ga-radiopharmaceuticals were analyzed by 1-way ANOVA multiple compar-
isons. Significance was reached when the probability (p) value was ≤0.05. Throughout
the manuscript, values are presented as mean ± the standard deviation (SD).
Results
TLC analysis
The HEPES reference sample of 0.02 mg/ml in water was prepared as described in the
Ph Eur. After 4 min incubation in iodine vapor, no bright yellow spot was visible (data
not shown).
Fig. 2 Examples of chromatograms with an isocratic system of NH4HCO2 20mM pH 9.5, UV 195 nm, from 0 to
4min of: an HEPES solution (top); a GA-DOTATOC (middle) solution and a [68Ga] GaDOTATOC solution (bottom)
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In the modified TLC method, after 4 min incubation (according to the Ph Eur) in the
iodine vapor chamber, none of the HEPES samples showed a (bright) yellow signal.
Moreover, incubation for 1 h in the iodine vapor chamber did also not result in a clear
signal for any of the spotted HEPES concentrations. Only after incubation of 2 h, the 1
mg/mL HEPES sample showed a yellow signal. This signal became more intense after
24 h incubation. Nevertheless, HEPES concentrations < 0.1 mg/mL did not show any
signal even after 24 h.
HPLC analysis
To validate the HPLC method a calibration curve was generated from an average of
three measurements containing 7 different concentrations of HEPES (Fig. 4). The cor-
relation coefficient of the calibration curve was r2 = 0.997 between the HEPES concen-
tration and the peak area in the range of 6–100 μg/mL. The HPLC method had an
inter-day (five replicate determinations in three consecutive days) reproducibility ran-
ging from 93 to 107% with a relative standard deviation (RSD) of 2.26% and an intra-
day (five replicate determinations in the same day) reproducibility ranging from 96 to
102% within an RSD of 2.30%, respectively. The accuracy was found to be 96 ± 0.12%
with a LOQ and a LOD of 3.23 and 0.97 μg/mL, respectively (Table 1).
Solvent effect
The intensity of HEPES peaks, when dissolved in different solutions, was found to be
not significantly different from each other (Table 2). However, the use of a matrix con-
taining 10% Ethanol in PBS shifted the retention time from 2.70 min to 2.60 min.
Revalidation of the methods
The TLC analysis performed with the solutions form institute B revealed once again
that none of the diluted concentrations were visible within any time frame (Fig. 3).
Only the stock solution of 1 mg/mL was clearly visible 2 h and 24 h after iodide incuba-
tion. For the HPLC comparison (Fig. 4), standard HEPES solutions prepared at two in-
stitutes were used to generate two calibration curves with linearity of r2 = 0.9993 and
0.9988 between the HEPES concentration and the peak area in the range of 6–100 μg/
Table 1 Parameters required for the validation of the HPLC method
Requirements Results
Retention time < 4min 2.8 min
Intra-day
Repeatability RSD < 5.00% 2.30%
Noise > 10 43
Inter-day
Reproducability F-test> 0.05 F-Test > 0.65
Linearity UV-detector R2 > 0.98 R2 = 0.99
LOD 3x noise 2.74 ± 0.24
LOQ 10x noise 9.40 ± 1.25
Carry over ≤0.10% 0.08%
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mL (Fig. 5a). The Pearson’s correlation coefficient of r = 0.9988 (Fig. 5b) confirmed the
significant relationship between both calibration curves.
HEPES analysis in different 68Ga-radiopharmaceuticals
The HEPES concentrations in the final formulations of [68Ga]Ga-DOTATOC,
[68Ga]Ga-PSMA-11 and [68Ga]Ga-NODAGA-Exendin that were analyzed by the HPLC
method are stated in Table 3.
Table 2 Effect of the solvent in the quantification of HEPES. Each solution was analyzed by HPLC
in triplicate
Solvent Retention time (min) Concentration of HEPES (μg/mL) t-test
(p)
Matrix (10% EtOH/PBS) 2.60 ± 0.01 9.35 ± 0.16 ____
NaCl 0.9% 2.69 ± 0.01 9.35 ± 0.29 0.99
PBS 2.70 ± 0.01 9.98 ± 0.40 0.09
Fig. 3 TLC of HEPES incubated in iodine chamber for 4 min; 1 h; 2 h and 24 h
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Discussion
Currently, only edotreotide ([68Ga]Ga-DOTATOC) radiolabeling is included in the Ph
Eur. In this procedure, HEPES is considered as an impurity and therefore a TLC
method for the detection of HEPES in [68Ga]Ga-DOTATOC is described. In the
present study, we describe a new TLC method and a sensitive HPLC method for the
quantification of HEPES present in 68Ga-radiopharmaceuticals. This HPLC method is
more reliable than the TLC assay described in Ph Eur. In addition, we also could not
detect the maximum amount stated by the Ph Eur (200 μg/volume of injected sample
(10 mL) e.g. 20 μg/mL) in the modified TLC method. In fact, in the modified TLC
method, the HEPES spots were only visible at concentrations higher than 1mg/mL
after 2 h of iodine incubation instead of 4 min as stated in the Ph Eur. Thus, this modi-
fied TLC method, as well as the method recommended by the Ph Eur, may not be suit-
able to use for a release requirement. With the new HPLC method, we were able to
Fig. 4 Chromatograms of HEPES in the range of 6–100 μg/mL with an isocratic system of NH4HCO2 20mM
pH 9.5, UV 195 nm, from 0 to 4 min
Fig. 5 a Calibration curves obtained with solutions prepared in two different institutes. b Comparison of
the 2 calibration curves
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have an LOQ of 3.2 μg/mL. These results are in similar range with a previously de-
scribed HPLC method where the LOQ was 10 μg/mL3 (Sasson et al. 2010).
With this new HPLC method, it was found that the presence of various solvents did
not affect the quantification of HEPES. This makes the method particularly useful when
various 68Ga-radiopharmaceuticals are formulated with different solutions. In addition,
with a retention time of 2.60–2.80 min it allows the QC to be performed within 4 min
and therefore suitable when a pre-release is required, as described in the Ph Eur. The
method is highly reproducible since we showed that when measuring a similar solution,
prepared by two different institutes, no significant differences were found between both
measurements (Fig. 5).
From the different 68Ga-radiopharmaceuticals that were analyzed, it was found that
only the amounts of HEPES present in [68Ga]Ga-NODAGA-Exendin were significantly
higher than the amounts found in the [68Ga]Ga-DOTATOC and [68Ga]Ga-PSMA-11
synthesized in the same institute. This difference is most likely due to the different la-
beling method used for [68Ga]Ga-NODAGA-Exendin.
In routine, in principle, a limit test to determine if the HEPES content is below the
maximum limit would be sufficient. Thus, the more reliable TLC method developed by
Pfaff et al. could be used in any nuclear medicine center (Pfaff et al. 2018). However,
even this method may sometimes give an overestimation of the HEPES amounts
present in a sample, risking the non-release of the radiopharmaceutical. Therefore, a
quantitative method like the HPLC would provide information not only of the total
HEPES amount present in the radiopharmaceutical but also, in case of the HEPES
amount is above the maximum limit, it can calculate the maximum volume that the
technician can take in order not to exceed the maximum limit, avoiding not releasing
the radiopharmaceutical. A clear example of this situation can be observed with the
[68Ga]Ga-NODAGA-Exendin. In the presence of the TLC methods only, none of the
[68Ga]Ga-NODAGA-Exendin could be released since their amount of HEPES exceeds
Table 3 Amounts of HEPES in different 68Ga-radiopharmaceuticals obtained from different




Maximum amount in VInj (μg)
a Maximum
VInj (mL)
Institute A (n = 3) 21 ± 4 171 ± 35 10 ± 2
Institute B (n = 6) 19 ± 8 150 ± 60 11 ± 1
Institute C ____ ____ ____
[68Ga]Ga-PSMA-11
Institute A (n = 3) 7 ± 10 58 ± 81 14 ± 3b
Institute B (n = 5) 8 ± 7 64 ± 54 16 ± 3b
Institute C ____ ____ ____
[68Ga]Ga-NODAGA-Exendin
Institute A (n = 3) 31 ± 1§ 291 ± 39 6 ± 1
Institute B (n = 3) 36 ± 5§ 245 ± 12 6 ± 1
Institute C (n = 3) 60 ± 8* 482 ± 69 2 ± 1
a When considering the recommended volume of injection of 8 mL. b When the amounts of HEPES were below LOQ, the
total volume of the radiopharmaceutical (VT = 16mL) was considered the maximum injected volume.
§ p < 0.05 when
comparing the HEPES concentration present in different radiopharmaceuticals obtained from the same institute.* p <
0.05 when comparing the HEPES concentration present in the same radiopharmaceutical obtained in different institutes
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the maximum limit. However, with the HPLC method, as long as the activity is
high enough, a smaller volume of the tracer could be injected in order not to ex-
ceed the maximum amount of HEPES (Table 3). One of the limitations of the
HPLC method is the need for an extra HPLC if the test needs to be performed be-
fore the release of the radiopharmaceutical. Thus, the HPLC method can only be
introduced in centers where there are at least 2 HPLC systems. In case this is not
possible the TLC method developed by Pfaff et al. could be implemented since
they showed similar results obtained with their TLC method compared to our
HPLC method.
Conclusion
The TLC method described in European Pharmacopoeia proved to be insufficiently
sensitive and thus unsuitable to use for QC release. The herewith presented HPLC
method is sensitive, quantitative, reproducible and suitable for QC release.
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